PMID: 8600085Mar 15, 1996Paper

Treatment of roentogenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low dose rate brachytherapy

International Journal of Radiation Oncology, Biology, Physics
M SaitoK Fujimori

Abstract

A prospective Phase II study was done to investigate the treatment results of combined external beam and intraluminal radiotherapy in roentogenographically occult inoperable endobronchial carcinoma. In 41 patients (all male) with roentogenographically occult endobronchial carcinoma, a combination of external beam radiotherapy using linac x-ray and intraluminal low dose rate brachytherapy via 192Ir thin wire (1.48 GBq) was performed. External beam radiotherapy comprised of 40 Gy in 20 fractions over 4 weeks was carried out, whereas intraluminal brachytherapy consisted of 25 Gy in five fractions over 2.5-5 weeks. The dose reference point for brachytherapy varied (3-9 mm) according to a diameter of the bronchus. Excluding two cases in which bronchoscopy was refused (1) and was still being treatment (1), 39 patients were treated according to plan. By the last intraluminal brachytherapy, no tumor was endoscopically identifiable in all cases. The follow-up period ranged from 1-41 months, with a median of 24.5 months. Recurrence occurred in two cases, with subsequent surgery: one is alive without cancer and the other died of uncontrolled lung cancer at 35 months. Radiation pneumonitis was observed in two cases for whom glucocorticoid ...Continue Reading

References

Sep 1, 1980·The Annals of Thoracic Surgery·N Martini, M R Melamed
Jul 1, 1994·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·G Sutedja, P E Postmus
Mar 15, 1993·International Journal of Radiation Oncology, Biology, Physics·B L Speiser, L Spratling
Jan 1, 1994·Respiration; International Review of Thoracic Diseases·G SutedjaP E Postmus
Mar 15, 1993·International Journal of Radiation Oncology, Biology, Physics·B L Speiser, L Spratling
Nov 1, 1963·Anesthesiology·N C STAUB

❮ Previous
Next ❯

Citations

Mar 15, 1996·International Journal of Radiation Oncology, Biology, Physics·B L Speiser
May 2, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·S SenanL H Murrer
Mar 11, 1998·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·T KoikeA Yokoyama
Oct 8, 1999·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·M FurutaK Tominaga
Feb 25, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·A TerziF Calabrò
Mar 8, 2000·International Journal of Radiation Oncology, Biology, Physics·F J LagerwaardS Senan
Mar 10, 2001·The New England Journal of Medicine·L M Seijo, D H Sterman
Apr 19, 2012·Journal of Cardiothoracic Surgery·Taichiro GotoRyoichi Kato
May 17, 2007·Physics in Medicine and Biology·H A GayC H Sibata
Sep 17, 2010·Expert Review of Molecular Diagnostics·Celine MascauxFred R Hirsch
Apr 17, 1999·Clinics in Chest Medicine·F D Sheski, P N Mathur

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Y NomotoT Nakagawa
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
M SatoS Fujimura
The Annals of Thoracic Surgery
N Martini, M R Melamed
© 2021 Meta ULC. All rights reserved